{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-020614","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2022-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.947036+00:00","generated_at":"2026-06-24T04:50:08.875136+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Corcept Q2 revenue $103.4M (up 13% YoY); EPS $0.24; reiterates FY22 revenue guidance","bullets":["Revenue $103.4M (Q2 2021: $91.6M); diluted EPS $0.24 vs $0.21.","Reiterated FY2022 revenue guidance of $400-$430 million.","Cash and investments $382.0 million, up $13.9 million from Q1 2022.","Initiated Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.","Expects Phase 2 AIWG (miricorilant) and NASH data in Q4 2022; NDA submission for relacorilant in Cushing's in H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-020614","json":"https://secwatch.observer/filing/0001628280-22-020614.json","markdown":"https://secwatch.observer/filing/0001628280-22-020614.md","text":"https://secwatch.observer/filing/0001628280-22-020614.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000162828022020614/0001628280-22-020614-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000162828022020614/cort-20220803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:50:08.875136+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}